Skip to content

A Randomized Controlled Clinical Study for Traditional Chinese Medicine to Improve the Clinical Benefit Rate of Advanced Esophageal Cancer

Clinical study of Traditional Chinese Medicine to Improve the Clinical Benefit Rate of Advanced Esophageal Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003504
Enrollment
Unknown
Registered
2020-07-21
Start date
2020-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Sponsors

Henan Province Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of Chinese and Western medicine; 2. Esophageal cancer patients who cannot undergo surgery, radiotherapy, chemotherapy or disease progression after chemotherapy; 3. Gender and age are not limited; 4. The estimated survival time was more than 20 days; 5. KPS score >= 40; 6. Those who could take traditional Chinese medicine orally before treatment; 7. The patient voluntarily signs the informed consent with the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients with mental illness who are difficult to cooperate with treatment; 3. Allergy to drugs; 4. Patients with severe liver, kidney, heart and hematopoietic system diseases; 5. There was no definite pathological diagnosis; 6. Have participated in other clinical research; 7. According to the researcher's judgment, other diseases or conditions that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in working environment and unstable living environment and other situations that are likely to cause patients to loss to follow-up.

Design outcomes

Primary

MeasureTime frame
TCM syndrome score;Survival rate of 42 days;KPS score;42 days quality of life;

Secondary

MeasureTime frame
Serum tumor markers (CEA, SCC, CA153, CA125, CA199);Safety indicator;T lymphocyte subsets (CD3, CD4, CD8, CD16, CD56), regulatory T cells (CD4 +, CD25 +, Foxp3);Remission of local lesions;

Countries

China

Contacts

Public ContactZheng yuling

Henan University of traditional Chinese Medicine & Henan Province Hospital of TCM

zhengyl@hactcm.edu.cn+86 0371-60905656

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026